Literature DB >> 18295505

The utility of LNA in microRNA-based cancer diagnostics and therapeutics.

Jan Stenvang1, Asli N Silahtaroglu, Morten Lindow, Joacim Elmen, Sakari Kauppinen.   

Abstract

MicroRNAs (miRNAs) are a novel class of small endogenous non-coding RNAs that regulate gene expression post-transcriptionally by binding to their cognate target mRNAs. Emerging evidence implies that miRNAs play important roles in cancer and thus, miRNAs have rapidly emerged as valuable markers for cancer diagnostics and promising targets for therapeutics. Locked nucleic acid (LNA) is a conformational RNA analoque that binds complementary RNA with unprecedented affinity and specificity. These properties make LNA well suited for miRNA detection and analysis for cancer diagnostics. Furthermore, recent studies on LNA-mediated silencing of miRNA function in vitro and in vivo support the potential of LNA in therapeutic intervention of cancer-associated miRNAs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295505     DOI: 10.1016/j.semcancer.2008.01.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  69 in total

Review 1.  The duality of oncomiR addiction in the maintenance and treatment of cancer.

Authors:  Christopher J Cheng; Frank J Slack
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

2.  MicroRNA-20a is essential for normal embryogenesis by targeting vsx1 mRNA in fish.

Authors:  Lei Sun; Heng Li; Xiaofeng Xu; Guanxiu Xiao; Chen Luo
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

3.  LNA-based oligonucleotide electrotransfer for miRNA inhibition.

Authors:  Sophie Chabot; Julie Orio; Romain Castanier; Elisabeth Bellard; Søren J Nielsen; Muriel Golzio; Justin Teissié
Journal:  Mol Ther       Date:  2012-05-22       Impact factor: 11.454

4.  The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation.

Authors:  Su Jung Song; Keisuke Ito; Ugo Ala; Lev Kats; Kaitlyn Webster; Su Ming Sun; Mojca Jongen-Lavrencic; Katia Manova-Todorova; Julie Teruya-Feldstein; David E Avigan; Ruud Delwel; Pier Paolo Pandolfi
Journal:  Cell Stem Cell       Date:  2013-07-03       Impact factor: 24.633

5.  mRNA quantification after fluorescence activated cell sorting using locked nucleic acid probes.

Authors:  Rie Maruo; Hiroya Yamada; Mikio Watanabe; Yoh Hidaka; Yoshinori Iwatani; Toru Takano
Journal:  Mol Biotechnol       Date:  2011-09       Impact factor: 2.695

Review 6.  MicroRNAs in myeloproliferative neoplasms.

Authors:  Huichun Zhan; Christopher Cardozo; Azra Raza
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

Review 7.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

Review 8.  Sequence-non-specific effects of RNA interference triggers and microRNA regulators.

Authors:  Marta Olejniczak; Paulina Galka; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2009-10-20       Impact factor: 16.971

9.  RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges.

Authors:  T F Duchaine; F J Slack
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

10.  miR-21: an oncomir on strike in prostate cancer.

Authors:  Marco Folini; Paolo Gandellini; Nicole Longoni; Valentina Profumo; Maurizio Callari; Marzia Pennati; Maurizio Colecchia; Rosanna Supino; Silvia Veneroni; Roberto Salvioni; Riccardo Valdagni; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  Mol Cancer       Date:  2010-01-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.